Table 1.
Demographic and Laboratory characteristics of patients at the time of genotype collection.
Fig 1.
Major drug resistance mutations in patients failing therapy and exposed to at least one PI.
Proportion of sequences with protease (PT) and reverse transcriptase (RT) mutations, presented by each resistance-associated codon, according to antiretroviral (ARV) class. (A) Major mutations to nucleoside RT inhibitors (NRTIs). (B) Major mutations to non-nucleoside RT inhibitors (NNRTI). (C) Major mutations to protease inhibitors (PI). Data according to the Stanford HIV Resistance Database.
Table 2.
Logistic regression to evaluate the association of demographic and laboratory variables to the presence of at least one protease inhibitor drug resistance mutation (PI-DRM).
Fig 2.
Protease inhibitors GSS and HIV-1 subtype.
Proportion of HIV-1 polymerase partial sequences by subtype (B, C and F), according to the genotypic susceptibility score (GSS) to Atazanavir (ATV), Darunavir (DRV) and Lopinavir (LPV). GSS determined at Stanford HIV Resistance Database as: SUSC. for: Susceptible; PLR. for: Potential Low Resistance; LLR. for: Low-Level Resistance; INT. for: Intermediate Resistance and HLR. for: High-Level Resistance to each antiretroviral.
Table 3.
Logistic regression to evaluate the association of demographic and laboratory variables to DRV susceptibility.
Table 4.
Percentage, by subtype, of protease inhibitor (PI) resistance mutations in the PI exposed group.
Table 5.
Logistic regression to evaluate the association of demographic and laboratory variables to the presence of I50LV mutations.